dc.contributor.author | Yang, M | |
dc.contributor.author | Vioix, H | |
dc.contributor.author | Hook, ES | |
dc.contributor.author | Hatswell, AJ | |
dc.contributor.author | Batteson, RL | |
dc.contributor.author | Gaumond, BR | |
dc.contributor.author | O'Brate, A | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Paik, PK | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2023-05-12T14:44:33Z | |
dc.date.available | 2023-05-12T14:44:33Z | |
dc.date.issued | 2023-02-18 | |
dc.identifier | S1098-3015(23)00056-6 | |
dc.identifier.citation | Value in Health, 2023, pp. S1098-3015(23)00056-6 - | en_US |
dc.identifier.issn | 1098-3015 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5786 | |
dc.identifier.eissn | 1524-4733 | |
dc.identifier.eissn | 1524-4733 | |
dc.identifier.doi | 10.1016/j.jval.2023.02.007 | |
dc.description.abstract | OBJECTIVES: The VISION trial showed durable activity of tepotinib in MET exon 14 (METex14) skipping non-small cell lung cancer. We analyzed health state utilities using patient-reported outcomes from VISION. METHODS: 5-level version of EQ-5D (EQ-5D-5L) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 responses were collected at baseline, every 6 to 12 weeks during treatment, and at the end of treatment and safety follow-up. EQ-5D-5L and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (QLU-C10D) utilities were derived using United States, Canada, United Kingdom, and Taiwan value sets, where available. Utilities were analyzed with linear mixed models including covariates for progression or time-to-death (TTD). RESULTS: Utilities were derived for 273/291 patients (EQ-5D-5L, 1545 observations; QLU-C10D, 1546 observations). Mean (± SD) US EQ-5D-5L utilities increased after tepotinib initiation, from 0.687 ± 0.287 at baseline to 0.754 ± 0.250 before independently assessed progression, and decreased post progression (0.704 ± 0.288). US QLU-C10D utilities showed similar trends (0.705 ± 0.215, 0.753 ± 0.195, and 0.708 ± 0.209, respectively). Progression-based models demonstrated a statistically significant impact of progression on utilities and predicted higher utilities pre versus post progression. TTD-based models showed statistically significant associations of TTD with utilities and predicted declining utilities as TTD decreased. Prior treatment (yes/no) did not significantly predict utilities in progression- or TTD-based models. Utilities for Canada, United Kingdom, and Taiwan showed comparable trends. CONCLUSIONS: In this first analysis of health state utilities in patients with METex14 skipping non-small cell lung cancer, who received tepotinib, utilities were significantly associated with progression and TTD, but not prior treatment. | |
dc.format | Print-Electronic | |
dc.format.extent | S1098-3015(23)00056-6 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier BV | en_US |
dc.relation.ispartof | Value in Health | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | MET exon 14 skipping | |
dc.subject | MET inhibitor | |
dc.subject | disease progression | |
dc.subject | health state utilities | |
dc.subject | non-small cell lung cancer | |
dc.subject | patient-reported outcomes | |
dc.subject | tepotinib | |
dc.subject | time-to-death | |
dc.title | Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-02-10 | |
dc.date.updated | 2023-05-12T14:43:43Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.jval.2023.02.007 | en_US |
rioxxterms.licenseref.startdate | 2023-02-18 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36805576 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.jval.2023.02.007 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof Robert Huddart) on 2023-05-12. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S1098301523000566-main.pdf | |